Clinical Trials Logo

Liver Diseases clinical trials

View clinical trials related to Liver Diseases.

Filter by:

NCT ID: NCT05184283 Terminated - Clinical trials for Hepatocellular Carcinoma

Utilization of MAsS in Patients Undergoing LT for HCC

Start date: June 16, 2022
Phase:
Study type: Observational

The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.

NCT ID: NCT05182983 Completed - Liver Diseases Clinical Trials

Tongue Image Database and Diagnostic Model for Digestive Tract Disease Diagnosis

Start date: November 15, 2020
Phase:
Study type: Observational

The tongue images of patients with gastrointestinal diseases and healthy people will be collected and the tongue image database will be established. Through deep learning and artificial intelligence, early screening models of various gastrointestinal tumors based on tongue images were constructed.

NCT ID: NCT05182099 Active, not recruiting - Liver Diseases Clinical Trials

High Resolution HBA-MRI Using Deep Learning Reconstruction

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

This study aims to compare image qualities between conventionally reconstructed MRI sequences and deep-learning reconstructed MRI sequences from the same data in patients who undergo Gd-EOB-DTPA enhanced liver MRI. The AIRTM deep learning sequence is applicable for various MRI sequences including T2-weighted image (T2WI), T1-weighted image and diffusion-weighted image (DWI). We plan to perform intra-individual comparisons of the image qualities between two reconstructed image datasets.

NCT ID: NCT05167305 Completed - Liver Diseases Clinical Trials

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease

Start date: December 22, 2021
Phase:
Study type: Observational

Hospital record of the patients of liver disease admitted from April-May 2021 and April-May 2019 will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and the subsequent 30 d and 90 day readmission rate. Monitoring and assessment: Hospital records of all patients of liver disease needing admission during the April-May 2019 and 2021, but without active COVID-19 infection, will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and 30 d and 90 d readmission rate.

NCT ID: NCT05135767 Active, not recruiting - Clinical trials for Alcohol Use Disorder

Biobehavioral Pathways Underlying Alcohol Use and Health

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

Alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) are intersecting diseases that add substantially to the global burden of disease and mortality. ALD refers to a spectrum of liver tissue injury caused by chronic and excessive alcohol use. Although reducing drinking is a main treatment goal, this is often unachievable for many patients with ALD due to an underlying AUD characterized by alcohol craving and drinking despite harms. While numerous, high-quality studies demonstrate effectiveness of brief psychosocial interventions for AUD, few trials have tested the efficacy of psychosocial interventions to reduce drinking in individuals with or at risk for ALD. This project establishes a team of addiction scientists and hepatologists to form a partnership and support future collaboration.

NCT ID: NCT05120557 Not yet recruiting - Liver Cirrhosis Clinical Trials

Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH

POCUS-NASH
Start date: September 2022
Phase: N/A
Study type: Interventional

The main objective of the study is to determine the diagnostic performances of an ultraportable diagnostic ultrasound system for the assessment of liver fibrosis severity in patients with NASH, and to compare them to other non-invasive tests.

NCT ID: NCT05116826 Completed - Liver Diseases Clinical Trials

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Start date: November 5, 2021
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.

NCT ID: NCT05088044 Recruiting - Liver Diseases Clinical Trials

A Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi

Start date: November 11, 2021
Phase: N/A
Study type: Interventional

In this study nurses will be taught regarding Modified Early Warning Score and how to mark the involved physiological parameters in the MEWS chart and then scoring will be given i.e MEWS score and according to the score intervention would be taken by nurses by communicating with other health team members. this scoring will allow nurses to assess early deterioration and early ICU admission and at last nurses will be asked regarding the barriers or facilitators they faced while performing MEWS score.

NCT ID: NCT05082077 Enrolling by invitation - Liver Diseases Clinical Trials

Global Utilization And Registry Database for Improved preservAtion of doNor Livers

Start date: March 15, 2022
Phase:
Study type: Observational [Patient Registry]

The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the LIVERguard system, as well as retrospective standard of care patients

NCT ID: NCT05062967 Not yet recruiting - Liver Diseases Clinical Trials

Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

The main objective of this study is to evaluate the prevalence and the clinical impact of Orthohepevirus C infection in different human populations, and to determine its zoonotic origin comparing the sequences obtained in both human and animal populations. This is an ambispective study where Orthohepevirus C infection will be evaluated in four high risk human population: i) patients with acute hepatitis, ii) patients with positive IgM antibody against Hepatitis E virus infection with undetectable viral load, iii) HIV infected individuals, and iv) solid organ transplant recipients. Furthermore, we will analyze three animal populations: i) suburban rodents, ii) domestic rodents, iii) wild carnivores. Viral sequences identified in both human and animal populations will be compared to evaluate the zoonotic origin of the infections.